IMUX
Immunic, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.72
−0.31%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -8.1%
- EBIT
- -12.0%
- EPS
- +36.6%
- Free cash flow
- +2.5%
- Operating cash flow
- +2.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +360.7%
- EPS
- +36.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- +3.4%
- EBIT
- -5.3%
- Net income
- +3.3%
- EPS
- +37.8%
- Free cash flow
- -1.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026